BACKGROUND AND OBJECTIVEFamilial Mediterranean fever (FMF) is characterized by recurrent and self-limiting attacks with peritonitis, pleuritis, arthritis, and erysipelas-like erythema. We aimed to investigate the red cell distribution width (RDW) level as an inflammatory marker in FMF patients compared with normal subjects.DESIGN AND SETTINGSA retrospective study of FMF patients at the Department of Gastroenterology, Cumhuriyet University, between November 2011-February 2013.METHODSA total of 249 FMF patients and 131 age- and sex-matched control participants were included in the currrent study. RDW levels were also analyzed by standard methods. Each patient was given 2 mL of blood sample to obtain genomic DNA.RESULTSStatistically significant differences were observed in RDW values between the FMF patients and the control group. Also, RDW levels were higher in the FMF patients with the homozygous M94V mutation compared with those with other mutations. The receiver-operating characteristic curve analysis suggested that the optimum RDW cutoff point for the FMF patients was 13.95, with a sensitivity, specificity, negative predictive value, and positive predictive value of 70%, 64%, 68%, and 66%, respectively (area under the curve: 0.711, 95% confidence interval 0.627–0.795, P<.0001).CONCLUSIONWe suggest that RDW may show subclinical inflammation in FMF patients. RDW may be a promising marker in predicting the homozygous M694V mutation in FMF patients.
Systematic inflammation, enhanced oxidative stress, and endothelial dysfunction are important for evolution and progression of renal damage, and they cause an increase in red cell distribution width (RDW). Familial Mediterranean fever (FMF) patients who are in the attack-free period and its relation with albuminuria and performance on assessment of microalbuminuria. One hundred and seventy-seven patients who had been diagnosed in accordance with Tel-hoshmer criteria and were in the attack-free period, and 143 age- and sex-matched healthy individuals were enrolled in our study. RDW values of FMF patients were higher compared with those of the controls (13.85 ± 1.07 and 13.15 ± 0.91, respectively; p < 0.0001). RDW values of FMF patients with microalbuminuria were higher compared with those of FMF patients with normoalbuminuria and the control group (p = 0.002 and p < 0.0001, respectively). RDW values of FMF patients with normoalbuminuria were higher compared with those of the control group (p < 0.0001). We have showed RDW levels are positively correlated with albuminuria (r = 0.185, p = 0.014). When assessing microalbuminuria with RDW in the patients, a cutoff value of 13.85 with sensitivity of 60%, specificity of 62%, and p = 0.002 (area under curve: 0.651, 95% confidence interval 0.563-0.738), was observed according to receiver-operating characteristic curve analysis. Among the various variables associated with albuminuria in multivariate logistic regression analyses, RDW remained an independent predictor of albuminuria (95% confidence interval 0.479-0.942, p = 0.021). RDW may be associated with albuminuria in FMF patients and it can be a predictor of microalbuminuria.
Objective: To evaluate neutrophil to lymphocyte ratio (NLR) and monocyte to lymphocyte ratio (MLR) in patients with gouty arthritis. Methods: Forty-five patients with gout and 45 healthy age and gender matched individuals, were included in this study. Clinical and laboratory data of patients during acute gouty arthritis (AGA) attack period, as well as in remission and control group data were reviewed and recorded from medical files. Patients were divided into two groups as having the arthritis attack and in remission. Results: NLR values were 4.19±3.37 in AGA patients, 2.64±1.74 in patients in remission, and 2.07±1.01 in controls. NLR values in AGA were higher than patients in remission and controls, whereas there was no difference between patients in remission, and controls (p<0.0001, p<0.0001, p=0.453; respectively). MLR values were 0.36±0.21 in AGA patients, 0.25±0.15 in patients in remission, and 0.22±0.06 in controls.MLR was higher in AGA patients than patients in remission, and controls, but there was no difference between patients in remission and healthy individuals (p<0.0001, p<0.0001, p=0.604; respectively). NLR and MLR values in AGA patients had positive correlations with CRP, ESR and leukocyte count. Thecut-off value of NLR was2.18 in ROC analysis (73% sensitivity, 63% specificity, AUC 0.676; p=0.004). The cutoff value of MLR was 0.22 in ROC analysis (62% sensitivity, 54% specificity, AUC 0.655; p=0.011). Conclusions: We concluded that MLR and NLR could be used as a cheap and useful inflammatory marker predicting arthritis attacks in patients with gout.
IntroductionChronic hepatitis C (CHC) infection is a systemic disorder that can lead to liver inflammation, fibrosis, cirrhosis, and hepatocellular cancer. The mean platelet volume (MPV) is widely used as an inflammatory marker to evaluate the platelet function and the status of systemic inflammation.AimTo determine the pre- and post-treatment MPV values in CHC patients who were administered a 48-week antiviral therapy based on systemic inflammation.Material and methodsWe enrolled 28 patients, diagnosed with CHC genotype 1b, who received a 48-week antiviral therapy and attended regular follow-up, and 28 healthy individuals. In diagnosing CHC, a positive anti-HCV for a minimum duration of 6 months and a positive serum HCV RNA were accepted as the criteria. The patients were assigned to one of two groups based on their group 1 (pre-treatment values) and group 2 (post-treatment values) after 3 months therapy. We analysed and compared the blood samples of all of the groups.ResultsThe MPV value was 8.89 ±1.20 in group 1 and 8.00 ±1.07 in group 2, and 8.21 ±1.18 in the control group. The value in group 1 was detected to be statistically significantly different from that in group 2 and the control group (p < 0.0001, p = 0.045, respectively). No statistically significant difference was observed between group 2 and the control group (p = 0.455).ConclusionsThe results of this study suggest that MPV could represent an inexpensive marker for use in assessing low-grade inflammation in patients with CHC.
BackgroundApelin is a glycoprotein, adipocytokine that plays an important role in decreasing the vascular inflammation on cardiovascular and metabolic disorders (1). Fetuin-A is also another glycoprotein that can be an acute phase protein negatively correlates with inflammation (2). Carotid intima-media thickness (C-IMT) may indicate vascular inflammation in primary Sjögren's syndrome (3). However, we do not know the relationship between serum apelin, fetuin-a levels and C-IMT in patients with Sjögren's syndrome.ObjectivesTo compare of the serum Apelin, Fetuin-A levels and C-IMT in patients with Sjögren's syndrome (SjS) and healthy controls.MethodsSixty-SjS patients and sixty healthy subjects were enrolled to this study. Serum apelin, fetuin-a levels were measured by ELISA. Concomitant C-IMT evaluations of the participants were performed. The BMI, insulin, HOMA-IR, lipid profiles were studied. Other laboratory parameters, autoantibody profiles, minor salivary gland biopsy scores (Chisholm) were obtained from patient's record files. The study was approved by the local ethics committee.ResultsThe median levels of apelin were 178.02±55.23 ng/mL in healthy subjects and 98.66±37.25 ng/mL in SjS (p<0.05) (Figure 1). The median levels of fetuin-a were 1370.3±81.74 ng/mL in control group and 1613±64.49 ng/mL in SjS group (p=0.021) (Figure 1). The C-IMT was negatively correlated with apelin levels in SjS patients (r= - 0.209, p=0.02). There was no significant correlation between fetuin-a levels and C-IMT in SjS (p=0.08). However, there were significant correletions between C-IMT and hemoglobin-A1c (r=0.353, p=0.005), C3 (r=0.36, p=0.004), C4 (r=0.351, p=0.005).ConclusionsWe found lower serum apelin and higher fetuin-a levels in SjS patients than in healthy subjects. Apelin and fetuin-a may be a new possible surrogate biomarker of inflammation in Sjögren's syndrome.ReferencesGualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007 Nov;17(8):275–83.Harman H, Tekeoğlu İ, Gürol G, et al. Comparison of fetuin-A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis. Int J Rheum Dis. 2016 Jan 22. doi: 10.1111/1756-185X.12791. [Epub ahead of print].Gravani F, Papadaki I, Antypa E, et al. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 2015 Apr 11;17:99. doi: 10.1186/s13075-015-0613-6.AcknowledgementWe would like to thank to “Cumhuriyet University Scientific Researches Project Unit (CUBAP)” for funding this project.Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.